-
TAILOR RT: A RANDOMIZED TRIAL OF REGIONAL RADIOTHERAPY IN BIOMARKER LOW RISK NODE POSITIVE BREAST CANCER
The purpose of this study is to determine whether there is any benefit of regional radiotherapy and to compare good and bad effects of not ...Phase
Interventional
-
AALL1731: A Phase 3 Trial Investigating Blinatumomab (IND# 117467 NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
While outcomes in SR B-ALL have improved significantly, this population still accounts for approximately half of the overall burden of relapse among children with ALL ...Phase
Interventional
-
AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
The goal of this trial is to reduce treatmentrelated morbidity and mortality without adversely impacting disease free survival (DFS) in Standard Risk (SR) patients, who ...Phase
Interventional
-
A Phase 3 Study of I-Metaiodobenzylguanidine or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
?The primary purpose of the study is to assess the effectiveness and safety of targeted radiopharmaceutical therapy with 131I-MIBG or crizotinib for patients with high-risk ...Phase
Interventional
-
Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours
The primary purpose of the study is to determine if accelerated BEP ((Bleomycin, Etoposide, and cisPlatin) is effective and tolerable for patients with advanced germ ...Phase
Interventional
-
ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727 IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
ACNS1833 is a prospective randomized phase 3 study comparing selumetinib to CV in previously untreated LGG not associated with neurofibromatosis or BRAFV600E. This non-inferiority study ...Phase
Interventional
-
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727 IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1(NF1)
The purpose of the study is to find out the safety and efficacy of the drug selumetinib in treating patients with low-grade glioma. We want ...Phase
Interventional
-
A Phase 3 Randomized Double-blind Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with MIBC (KEYNOTE-992)
The purpose of the study is to determine the safety and efficacy of Pembrolizumab (MK-3475) and Chemoradiotherapy (CRT) for people who have muscle-invasive bladder cancer ...Phase
Interventional
-
A Phase 3 Trial Investigating Blinatumomab (IND#117467 NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma(B-LLy)
The purpose of the trial is to determine the safety and efficacy of the investigational medicine, blinatumomab plus standard treatment for patients who have Standard ...Phase
Interventional
-
ACNS1831: A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
The purpose of the study is to compare the efficacy of two treatments. The purpose is to determine whether the efficacy of treatment with selumetinib ...Phase
Interventional
